Management of T-cell lymphoma patients requires bone marrow examination for the assessment of stage and prognosis (1 ,2 ). Bone marrow biopsy (BMB) is mandatory when bone marrow aspirate is not successful (e.g., in cases of patchy lymphomatous infiltration or induction of fibrosis [“dry aspirate”]) (3 ). Moreover, BMB has some advantages over aspirate, such as examination of a greater volume of tissue with preserved architecture, assessment of cellularity, and application of immunohistochemistry.
